Outsourcing Ethics: How a Controversial Infant Vaccine Trial Found Its Way to Africa

When Western health authorities and academic institutions decide to test their hypotheses, they occasionally find domestic regulations inconvenient. The solution, it seems, is simple enough: relocate the experiment to a country where administrative oversight is far more accommodating.

A newly approved clinical trial in Guinea-Bissau demonstrates how smoothly this dynamic functions. Researchers from the University of Southern Denmark plan to enroll 14,000 newborns in a study testing the delay of the hepatitis B vaccine. Half of the infants will receive the recommended shot at birth, while the other half will have it withheld for their first six weeks of life. The trial has secured greenlights from both local officials in Guinea-Bissau and an institutional ethics committee in Denmark, alongside $1.6 million in funding from the US Centers for Disease Control and Prevention, supplemented by private American foundations including the Pershing Square Foundation and the Bluebell Foundation.

The setup is striking given the medical realities on the ground. In Guinea-Bissau, roughly 18 percent of adults carry hepatitis B, a virus that survives on surfaces for up to a week and spreads easily through casual household contact. While an updated study protocol now screens mothers prior to birth and excludes infants of positive mothers, the testing method carries a five percent false negative rate. It also leaves infants vulnerable to casual exposure from other relatives and caregivers during their earliest days, when the risk of developing chronic liver conditions from infection is highest.

To secure approval for such a study, procedural gymnastics were required. Denmark’s national ethics body had no jurisdiction over trials conducted outside its borders. Consequently, the local ethics committee at the University of Southern Denmark altered its own internal regulations to vote on the project. The decision was contentious enough that four committee members, including one of the primary reviewers, resigned in protest over placing infants in a research lottery that exposes them to preventable disease.

The political backing for the project is equally notable. Robert F. Kennedy Jr., head of the US Department of Health and Human Services, has publicly lauded the Danish researchers behind the Bandim Health Project, describing them in glowing terms and holding up their work as an ideal model for questioning established vaccine schedules. The research also arrives at an opportune moment: Guinea-Bissau recently postponed its planned universal newborn hepatitis B vaccination campaign from 2027 to 2028.

This alignment of state funding, private capital, and convenient policy delays raises an obvious question for public health governance. When international standard care mandates immediate protection against a severe disease, creating a six-week window of vulnerability in thousands of infants under the banner of scientific inquiry looks less like rigorous medical progress and more like an exercise in institutional indulgence.

Written by Sandy van Dongen sandy.vandongen@alpineweekly.com